Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo - Wikidata - awgldk - TriplyDB

Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo

Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo

http://www.wikidata.org/entity/Q37377754

about

Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and Cancer Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma Heparan sulfate signaling in cancer The niche factor syndecan-1 regulates the maintenance and proliferation of neural progenitor cells during mammalian cortical development Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.Anoikis mediators in oral squamous cell carcinoma.Microvesicles secreted from human multiple myeloma cells promote angiogenesis.Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells.MicroRNA-143 targets Syndecan-1 to repress cell growth in melanoma Progress in myeloma stem cells Myeloma as a model for the process of metastasis: implications for therapy Syndecan-1 identifies and controls the frequency of IL-17-producing naïve natural killer T (NKT17) cells in mice.Chemical synthesis of a heparan sulfate glycopeptide: syndecan-1.An introduction to proteoglycans and their localization Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma.Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.Proteoglycans and their roles in brain cancer.Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix.Interstitial cell migration: integrin-dependent and alternative adhesion mechanisms.Syndecan-1 Acts as an Important Regulator of CXCL1 Expression and Cellular Interaction of Human Endometrial Stromal and Trophoblast Cells Molecular functions of syndecan-1 in disease.Syndecans as modulators and potential pharmacological targets in cancer progression.Fell-Muir Lecture: Syndecans: from peripheral coreceptors to mainstream regulators of cell behaviour.Interactions of signaling proteins, growth factors and other proteins with heparan sulfate: mechanisms and mysteries.Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells.Strychnos nux-vomica root extract induces apoptosis in the human multiple myeloma cell line-U266B1.Syndecan-1-coating of interleukin-17-producing natural killer T cells provides a specific method for their visualization and analysis.Angiogenesis and multiple myeloma.Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.CD138+ cell separation affects cancer gene expression in human myeloma cell lines.Dually modified transmembrane proteoglycans in development and disease.Molecular targets and signaling pathways regulated by nuclear translocation of syndecan-1.Syndecan-1 regulates adipogenesis: new insights in dedifferentiated liposarcoma tumorigenesis.Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma.

P2860

Q26740617-36B64D75-FFD5-4122-8B2E-B0C79579CEB8 Q27001749-F1F1EC12-D224-4BB7-A476-5711C2FFA1BE Q28657828-6C5FA10C-529C-4E25-AFCF-FDDE585DC5F7 Q31088269-80E9E766-673E-465E-BA21-F491F7450291 Q33754644-BD478B11-347A-4DB4-85E2-3FA9484AB9F3 Q33820610-2AD0EA2F-FF3A-454A-86CB-7E8A8F03D549 Q34675956-29F49E38-7224-4E29-8E56-91A772C926F1 Q34694466-F20C256F-47C3-42A6-816A-9E44DE967A79 Q34770470-D73D5B7A-E099-431A-8A71-240E3D1BFBCF Q35077269-12B3D5A7-424B-45A5-8C63-250B2E73A6ED Q35078198-273EF713-F8F8-4F30-8B27-EE09BB680A4F Q35145657-D2E77255-A6EE-4020-A3E0-5F55449EBB67 Q35824980-E3318FE0-D788-41E7-BA01-AE078A5854F1 Q36079800-3A86C49E-0EA2-4EB5-A4F6-C678A419BDDC Q36365809-226AF5F7-D0C4-4449-A4F8-8E294D3D390F Q36452712-5B13F97D-D27C-4BAE-9238-AFC78852D2EB Q36481630-7C714251-9D6E-4635-B23B-2439A786C404 Q36527905-C585DFB6-E10B-4D24-9CD3-B5DA1B3BE45F Q36787608-612CFF83-2D09-4889-B548-6AD8931F8CD4 Q36816444-F4AB2BE5-E2B6-4AE9-BEBF-8DFDE4B618C5 Q37499263-3C4C3F4E-718F-49F4-9BDE-AC76D9DA82B5 Q37608433-EAD33CDD-BEE0-4B63-B758-B5C90556CC6D Q37610995-1542C1FD-C7B5-4607-AF3A-37929F986E73 Q37634379-96AFC85F-6E32-455E-9624-C075005CC0ED Q37672798-66403773-CD48-4BDA-A564-841A71A84203 Q37950202-F984B831-0B82-4B3B-B4EB-50DB85653AE0 Q38189392-C2DE1417-B4EA-47C1-9F5F-40319E2015F8 Q38302621-51045EC4-136A-49E1-A361-F23197340FC8 Q38528036-DF06399C-50E4-4714-B3E3-9C1D5BC1FACD Q38760595-6BA396F7-CE4D-47A0-B08A-41A5E594620D Q39144769-32D8A1F4-F864-4858-82CD-E54A7CF8A000 Q39224279-511C06F9-C197-433A-959B-300EAD421459 Q39279449-C064C526-D04B-43A2-8648-AD27AACC4E9D Q39696428-0353A341-A3B1-4C0B-8CC4-0A67BA215A79 Q42064478-DB477C11-5B23-448A-84D0-818ED940101F Q44881013-40F6B264-6B04-497C-A604-38B7ED266429 Q47240245-206766E8-12AF-443A-B3D8-2C01E8B7E98D Q47318797-4B83D2FD-AEF1-479C-BA0C-BC473887AC4D Q51040058-0A50424D-2659-4749-8E2F-DFF1C0475CE2 Q55208548-4564CD1F-73C6-4998-A729-64763E230E35

P2860

Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo

http://www.wikidata.org/entity/Q37377754

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Syndecan-1 is required for rob ...... asis of myeloma tumors in vivo

@en

Syndecan-1 is required for rob ...... sis of myeloma tumors in vivo.

@nl

type

label

Syndecan-1 is required for rob ...... asis of myeloma tumors in vivo

@en

Syndecan-1 is required for rob ...... sis of myeloma tumors in vivo.

@nl

prefLabel

Syndecan-1 is required for rob ...... asis of myeloma tumors in vivo

@en

Syndecan-1 is required for rob ...... sis of myeloma tumors in vivo.

@nl

P1433

Q37377754-2AD91C08-34AE-438D-A802-488DB4DB7B2B

P1476

Q37377754-19DB20F5-B02A-4055-88E0-C5A137226D8A

P2093

Q37377754-6133B6A3-B56B-418E-B5A7-04065644306C

Q37377754-692C6D86-D2D7-4F86-8A76-034D56D37C12

Q37377754-8FCA2710-D8B2-464F-83FC-58CA26BD5F60

Q37377754-94DFCA0A-1E76-4361-B89A-9236C83AD7EB

Q37377754-9E743291-02EC-46F8-90F4-1821CD497D9B

Q37377754-C5D51999-9273-41FA-B5C6-FA6646926639

Q37377754-FA1A967A-7927-4617-AFE6-4CA5BEC429A0

P2860

Q37377754-1B877F1A-EB2B-4C16-9FE1-BCB6D510D1D4

Q37377754-23829FA2-AFF1-4139-A655-5689AC0D8C0E

Q37377754-251B8435-A3B8-497E-9C07-06AEB04918E5

Q37377754-26C6A4E5-BCBF-42D8-8968-2461E9388F9B

Q37377754-30E3BFE8-2ED3-4A30-B26F-34EAF0E92AF8

Q37377754-4519B21B-D2BC-42FC-9EE0-134ACF26A4C3

Q37377754-45FCF96B-70DC-4DC3-A90B-F4C063001DED

Q37377754-563223EF-36C0-4D3F-B1AA-86BF6857DA48

Q37377754-7E26F2B7-82F1-4FE8-9EDC-01CF28F5F1E6

Q37377754-81615C9C-C11D-41A2-B6AE-68D1B2E0EAA1

P304

Q37377754-E64E87F7-94CD-46FE-85F4-64A161CF3C4C

P31

Q37377754-C8951109-3727-4013-BFF5-BB69C9D53F4A

P356

Q37377754-DC0ED0E2-248D-4E43-B2BD-7B52EEB7CE53

P407

Q37377754-87595782-F6C5-4035-967E-B6034663CF29

P433

Q37377754-210629DC-5FA6-4D4C-90A3-41393D700EEE

P478

Q37377754-6EB27C02-0646-4A61-81EC-4161378C6B13

P577

Q37377754-361F0729-F46C-46E7-8DB2-71EF20B2445B

P698

Q37377754-796DFE7D-5700-48D5-BB73-9B179617C650

P932

Q37377754-22000996-8815-4DEF-AA1B-91E690D5E7D5

P356

JBC.M109.018473

P1433

Journal of Biological Chemistry

P1476

Syndecan-1 is required for rob ...... asis of myeloma tumors in vivo

@en

P2093

Joseph P Ritchie

http://www.w3.org/2001/XMLSchema#string

Kurt Zinn

http://www.w3.org/2001/XMLSchema#string

Ralph D Sanderson

http://www.w3.org/2001/XMLSchema#string

Veronica MacLeod

http://www.w3.org/2001/XMLSchema#string

Yang Yang

http://www.w3.org/2001/XMLSchema#string

Yekaterina B Khotskaya

http://www.w3.org/2001/XMLSchema#string

Yuemeng Dai

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of clonogenic multiple myeloma cells

Molecular cloning of syndecan, an integral membrane proteoglycan

Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis

High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity

Soluble syndecan-1 promotes growth of myeloma tumors in vivo

HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo.

Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery.

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.

Enhancement of clonogenicity of human multiple myeloma by dendritic cells

Heparan sulfate proteoglycans from mouse mammary epithelial cells: localization on the cell surface with a monoclonal antibody

P304

26085-26095

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M109.018473

http://www.w3.org/2001/XMLSchema#string

P407

P433

38

http://www.w3.org/2001/XMLSchema#string

P478

284

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19596856

http://www.w3.org/2001/XMLSchema#string

P932

2758008

http://www.w3.org/2001/XMLSchema#string